Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Jul;5(Suppl 3):e000836.
doi: 10.1136/esmoopen-2020-000836.

Can multigene assays widen their clinical usefulness in early breast cancer treatment choice during the current COVID-19 outbreak in Italy?

Alberto Zambelli  1 , Carlo Alberto Tondini  2
Affiliations
Comment

Can multigene assays widen their clinical usefulness in early breast cancer treatment choice during the current COVID-19 outbreak in Italy?

Alberto Zambelli et al. ESMO Open. 2020 Jul.
No abstract available

Keywords: Covid-19; breast cancer; multigene assays; neoadjuvant endocrine therapy.

PubMed Disclaimer

Conflict of interest statement

Competing interests: AZ reports honoraria fees from Roche, Pfeizer, Eli Lilly, Novartis, Genomic Health and Astra Zeneca, outside the submitted work. CAT reports personal fees from Roche, Pfeizer, Eli Lilly, Novartis, Genomic Health and Astra Zeneca outside the submitted work

Comment on

References

    1. Cardoso F, Kyriakides S, Ohno S, et al. . ESMO guidelines Committee. Ann Oncol 2019;30:1674. - PubMed
    1. Iwata H, Masuda N, Yamamoto Y, et al. . Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study. Breast Cancer Res Treat 2019;173:123–33. 10.1007/s10549-018-4964-y - DOI - PMC - PubMed
    1. Dubsky PC, Fesl C, Singer CF, et al. . The EndoPredict score predicts residual cancer burden to neoadjuvant chemotherapy and to Neo-Endocrine therapy in HR+/HER2- breast cancer patients from ABCSG 34. SABCS Dec 5-9, 2017.
    1. Whitworth P, Beitsch P, Mislowsky A, et al. . Chemosensitivity and endocrine sensitivity in clinical luminal breast cancer patients in the prospective neoadjuvant breast registry symphony trial (NBRST) predicted by molecular subtyping. Ann Surg Oncol 2017;24:669–75. 10.1245/s10434-016-5600-x - DOI - PMC - PubMed
    1. Prat A, Saura C, Pascual T, et al. . Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol 2020;21:33–43. 10.1016/S1470-2045(19)30786-7 - DOI - PubMed